SI3131928T2 - Trifunkcionalna molekula za vezavo antigena - Google Patents

Trifunkcionalna molekula za vezavo antigena

Info

Publication number: SI3131928T2
Authority: SI; Slovenia
Prior art keywords: binding molecule; trifunctional antigen; trifunctional; antigen; molecule
Prior art date: 2014-04-13

Application number

SI201531107T

Other languages

English (en)

Other versions

SI3131928T1 (sl

Inventor

Melvyn Little

Eugene Zhukovsky

Markus Eser

Michael Weichel

Thorsten Gantke

Uwe Reusch

Kristina Ellwanger

Gall Fabrice Le

Original Assignee

Affimed Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-13

Filing date

2015-04-12

Publication date

2023-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50478320&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3131928(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-12 Application filed by Affimed Gmbh filed Critical Affimed Gmbh

2020-04-30 Publication of SI3131928T1 publication Critical patent/SI3131928T1/sl

2023-05-31 Publication of SI3131928T2 publication Critical patent/SI3131928T2/sl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SI201531107T 2014-04-13 2015-04-12 Trifunkcionalna molekula za vezavo antigena SI3131928T2 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14164523.4A EP2930188A1 (en)	2014-04-13	2014-04-13	Trifunctional antigen-binding molecule
PCT/EP2015/057919 WO2015158636A1 (en)	2014-04-13	2015-04-12	Trifunctional antigen-binding molecule
EP15719420.0A EP3131928B2 (en)	2014-04-13	2015-04-12	Trifunctional antigen-binding molecule

Publications (2)

Publication Number	Publication Date
SI3131928T1 SI3131928T1 (sl)	2020-04-30
SI3131928T2 true SI3131928T2 (sl)	2023-05-31

Family

ID=50478320

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201531107T SI3131928T2 (sl)	2014-04-13	2015-04-12	Trifunkcionalna molekula za vezavo antigena

Country Status (13)

Country	Link
US (2)	US20170037128A1 (sl)
EP (2)	EP2930188A1 (sl)
JP (1)	JP6635940B2 (sl)
KR (1)	KR102392598B1 (sl)
CN (1)	CN106661108A (sl)
AU (1)	AU2015249006B2 (sl)
BR (1)	BR112016023362A2 (sl)
CA (1)	CA2945053A1 (sl)
DK (1)	DK3131928T4 (sl)
MX (1)	MX2016013218A (sl)
RU (1)	RU2753882C2 (sl)
SI (1)	SI3131928T2 (sl)
WO (1)	WO2015158636A1 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP2016009586A0 (en)	2014-05-29	2016-11-30	Macrogenics Inc	Tri-specific binding molecules and methods of use thereof
MA44381A (fr)	2015-06-15	2019-01-23	Numab Innovation Ag	Format d'anticorps hétérodimères multispécifiques
EP3156417A1 (en)	2015-10-13	2017-04-19	Affimed GmbH	Multivalent fv antibodies
AU2018219887A1 (en)	2017-02-08	2019-08-22	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
ES2955074T3 (es)	2017-02-20	2023-11-28	Dragonfly Therapeutics Inc	Proteínas que se unen a HER2, NKG2D Y CD16
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US20200325232A1 (en) *	2017-11-21	2020-10-15	Innate Pharma	Multispecific antigen binding proteins
RU2020120411A (ru) *	2017-11-21	2021-12-23	Новартис Аг	Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения
BR112020016190A2 (pt)	2018-02-08	2020-12-15	Dragonfly Therapeutics, Inc.	Domínios variáveis de anticorpos direcionando o receptor nkg2d
CA3090464A1 (en) *	2018-03-14	2019-09-19	Affimed Gmbh	Bispecific egfr/cd16 antigen-binding protein
CN111566127A (zh) *	2018-03-27	2020-08-21	西雅图免疫公司	制导和导航控制蛋白及其制备和使用方法
JOP20200303A1 (ar)	2018-05-24	2020-11-23	Janssen Biotech Inc	عوامل ربط psma واستخداماتها
US11845797B2 (en)	2018-07-03	2023-12-19	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
BR112021003436A2 (pt)	2018-08-27	2021-05-18	Affimed Gmbh	células nk criopreservadas pré-carregadas com uma construção de anticorpo
EP3956022A1 (en)	2019-04-19	2022-02-23	Janssen Biotech, Inc.	Methods of treating prostate cancer with an anti- psma/cd3 antibody
CA3160927A1 (en)	2019-12-27	2021-07-01	Affimed Gmbh	Method for the production of bispecific fcyriii x cd30 antibody construct
IL300314A (en)	2020-10-08	2023-04-01	Affimed Gmbh	Coupling materials with triple specificity
EP4247850A1 (en)	2020-11-20	2023-09-27	Simcere Innovation, Inc.	Armed dual car-t compositions and methods for cancer immunotherapy
AU2022214491A1 (en)	2021-01-28	2023-09-14	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
GB2623199A (en)	2021-04-08	2024-04-10	Marengo Therapeutics Inc	Multifunctional molecules binding to TCR and uses thereof
CA3216098A1 (en)	2021-07-30	2023-02-02	Uwe Reusch	Duplexbodies
CN114044822B (zh) *	2021-10-28	2023-06-27	杭州博茵生物技术有限公司	血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用
CN114316060B (zh) *	2021-12-15	2023-06-13	北京市肿瘤防治研究所	抗人cd19与cd206双特异性抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994013804A1 (en)	1992-12-04	1994-06-23	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
UA40577C2 (uk) *	1993-08-02	2001-08-15	Мерк Патент Гмбх	Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
WO1998003670A1 (en) *	1996-07-23	1998-01-29	Tanox Pharma B.V.	Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP1293514B1 (en) *	2001-09-14	2006-11-29	Affimed Therapeutics AG	Multimeric single chain tandem Fv-antibodies
RU2004122702A (ru) *	2001-12-26	2005-04-20	Иммуномедикс, Инк. (Us)	Способы получения полиспецифичных, поливалентных средств из vh и vl доменов
DK1673398T3 (da) *	2003-10-16	2011-04-18	Micromet Ag	Multispecifikke, deimmuniserede CD3-bindere
SG193141A1 (en) *	2005-12-21	2013-09-30	Amgen Res Munich Gmbh	Pharmaceutical compositions with resistance to soluble cea
US9029508B2 (en) *	2008-04-29	2015-05-12	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
CN102448985B (zh) *	2009-05-27	2015-08-05	霍夫曼-拉罗奇有限公司	三或四特异性抗体
EP2332994A1 (en) *	2009-12-09	2011-06-15	Friedrich-Alexander-Universität Erlangen-Nürnberg	Trispecific therapeutics against acute myeloid leukaemia
TWI545134B (zh) *	2010-10-22	2016-08-11	西雅圖遺傳學公司	以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴｍＴＯＲ路徑抑制劑間的協同功效

2014
- 2014-04-13 EP EP14164523.4A patent/EP2930188A1/en not_active Withdrawn
2015
- 2015-04-12 AU AU2015249006A patent/AU2015249006B2/en active Active
- 2015-04-12 EP EP15719420.0A patent/EP3131928B2/en active Active
- 2015-04-12 WO PCT/EP2015/057919 patent/WO2015158636A1/en active Application Filing
- 2015-04-12 DK DK15719420.0T patent/DK3131928T4/da active
- 2015-04-12 CA CA2945053A patent/CA2945053A1/en active Pending
- 2015-04-12 JP JP2016562499A patent/JP6635940B2/ja active Active
- 2015-04-12 RU RU2016138347A patent/RU2753882C2/ru active
- 2015-04-12 MX MX2016013218A patent/MX2016013218A/es unknown
- 2015-04-12 KR KR1020167030836A patent/KR102392598B1/ko active IP Right Grant
- 2015-04-12 SI SI201531107T patent/SI3131928T2/sl unknown
- 2015-04-12 CN CN201580019685.7A patent/CN106661108A/zh active Pending
- 2015-04-12 BR BR112016023362A patent/BR112016023362A2/pt active Search and Examination
2016
- 2016-10-11 US US15/290,255 patent/US20170037128A1/en not_active Abandoned
2021
- 2021-11-03 US US17/517,869 patent/US20220048994A1/en active Pending

Also Published As

Publication number	Publication date
RU2753882C2 (ru)	2021-08-24
EP3131928A1 (en)	2017-02-22
EP3131928B1 (en)	2019-11-20
CN106661108A (zh)	2017-05-10
JP2017513476A (ja)	2017-06-01
KR20160143739A (ko)	2016-12-14
EP3131928B2 (en)	2023-04-05
WO2015158636A8 (en)	2016-11-17
MX2016013218A (es)	2017-05-19
SI3131928T1 (sl)	2020-04-30
DK3131928T3 (da)	2020-02-24
EP2930188A1 (en)	2015-10-14
BR112016023362A2 (pt)	2018-03-27
CA2945053A1 (en)	2015-10-22
WO2015158636A1 (en)	2015-10-22
RU2016138347A (ru)	2018-05-14
US20170037128A1 (en)	2017-02-09
DK3131928T4 (da)	2023-05-30
US20220048994A1 (en)	2022-02-17
RU2016138347A3 (sl)	2018-12-04
AU2015249006A1 (en)	2016-10-20
JP6635940B2 (ja)	2020-01-29
KR102392598B1 (ko)	2022-04-29
AU2015249006B2 (en)	2020-10-29

Publication	Publication Date	Title
SI3131928T1 (sl)	2020-04-30	Trifunkcionalna molekula za vezavo antigena
IL250583A0 (en)	2017-04-30	Anti-tigit antibodies
ZA201605660B (en)	2022-05-25	Multispecific antibodies
PL3227332T3 (pl)	2020-06-15	Wielospecyficzne przeciwciała
SG11201703403TA (en)	2017-05-30	Anti-tim-3 antibodies
SG11201703346PA (en)	2017-05-30	Anti-tim-3 antibodies
GB201414823D0 (en)	2014-10-01	Multispecific antibodies
GB201421379D0 (en)	2015-01-14	Molecule
IL252422B (en)	2018-06-28	Effector-deficient anti-cd32a antibodies
IL250374B (en)	2021-04-29	Antibodies against ceramide
IL246603B (en)	2020-01-30	A new antibody against netrin-1
PL3112463T3 (pl)	2020-03-31	Nowe przeciwciało przeciwko presepsynie
GB201409759D0 (en)	2014-07-16	Molecule
GB201403479D0 (en)	2014-04-16	Molecule
GB201419089D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201419092D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201417614D0 (en)	2014-11-19	Antibodies
GB201414270D0 (en)	2014-09-24	Antibodies
GB201405775D0 (en)	2014-05-14	Antibodies
GB201401200D0 (en)	2014-03-12	Antibodies